Ekinakozit PC3 androjen bağımsız prostat kanseri hücrelerinde hücre proliferasyonunu azaltır ve hücre invazyonunu inhibe eder-Reference-Cited by-同舟云学术

Ekinakozit PC3 androjen bağımsız prostat kanseri hücrelerinde hücre proliferasyonunu azaltır ve hücre invazyonunu inhibe eder

Published:2022-08-12 Issue: Volume: Page:
ISSN:1309-9833
Container-title:Pamukkale Medical Journal
language:tr
Short-container-title:Pam Tıp Derg

Author:

SEÇME Mücahit¹,DODURGA Yavuz²

Affiliation:

1. ORDU UNIVERSITY

2. PAMUKKALE ÜNİVERSİTESİ, TIP FAKÜLTESİ

Abstract

Purpose: The aim of this study was to determine the effects of Echinacoside on cell proliferation, invasion and mRNA expression changes of invasion-related genes in PC3 androgen-independent prostate cancer cells. Material Methods: The effect of Echinacoside on cell proliferation in PC3 cells was determined by XTT method. Anti-invasive efficacy was achieved using the transwell chamber. Total RNA isolation was performed by Trizol and cDNA was subsequently synthesized. mRNA expression changes of MMP2,MMP9, TIMP1, TIMP2 and TIMP3 were also performed in RT-PCR with SYBER Green. Results: In this study, the IC50 dose of Echinacoside in PC3 cells was determined as 55.21 μM at 48th hour. It was determined that echinacoside inhibited cell invasion in PC3 cells and reduced the invasion by 66% in the dose group. In addition, it was found statistically significant that Echinacoside increased TIMP 1 mRNA expression 1.96 times, TIMP2 mRNA expression 2.60 times, while decreasing MMP2 expression 3.82 times and MMP9 mRNA expression 1.54 times. Conclusion: In conclusion, it was revealed that echinacoside has an anti-proliferative effect on PC3 prostate cancer cells. It has also been shown that invasion-related genes can suppress invasion by regulating expression changes. With this study, preliminary data were presented in terms of detailed molecular biological studies to be carried out on echinacoside and its effect on prostate cancer.

Publisher

Pamukkale University

Subject

General Medicine

Reference30 articles.

1. 1- NGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., et al. (2017). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology, 3(4), 524–548. https://doi.org/10.1001/jamaoncol.2016.5688

2. 2- H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Oxidative Medicine and Cellular Longevity worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.

3. 3- Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: a cancer journal for clinicians, 72(1), 7–33. https://doi.org/10.3322/caac.21708

4. 4- Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Jr, Dotan, Z. A., Fearn, P. A., & Kattan, M. W. (2006). Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. Journal of the National Cancer Institute, 98(10), 715–717. https://doi.org/10.1093/jnci/djj190

5. 5- Fontana, F., Raimondi, M., Marzagalli, M., Di Domizio, A., & Limonta, P. (2020). Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets. Cells, 9(2), 460. https://doi.org/10.3390/cells90204603w